Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs

Ben Gary Harvey, Neil R. Hackett, Tarek El-Sawy, Todd K. Rosengart, Edward A. Hirschowitz, Michael D. Lieberman, Martin L. Lesser, Ronald Crystal

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Administration of adenovirus (Ad) vectors to immunologically naive experimental animals almost invariably results in the induction of systemic anti-Ad neutralizing antibodies. To determine if the human systemic humoral host responses to Ad vectors follow a similar pattern, we evaluated the systemic (serum) anti-Ad serotype 5 (Ad5) neutralizing antibodies in humans after administration of first generation (E1- E3-) Ad5-based gene transfer vectors to different hosts. Ad(GV)CFTR.10 (carrying the normal human cystic fibrosis [CF] transmembrane regulator cDNA) was sprayed (8 x 107 to 2 x 1010 particle units [PU]) repetitively (every 3 months or every 2 weeks) to the airway epithelium of 15 individuals with CF. Ad(GV)CD.10 (carrying the Escherichia coli cytosine deaminase gene) was administered (8 x 108 to 8 x 109 PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer and by the intradermal route (8 x 107 to 8 x 109 PU, single administration) to six healthy individuals. Ad(GV)VEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 108 to 4 x 109.5 PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease. Ad vector administration to the airways of individuals with CF evoked no or minimal serum neutralizing antibodies, even with repetitive administration. In contrast, intratumor administration of an Ad vector to individuals with metastatic colon cancer resulted in a robust antibody response, with anti-Ad neutralizing antibody titers of 102 to >104. Healthy individuals responded to single intradermal Ad vector variably, from induction of no neutralizing anti-Ad antibodies to titers of 5 x 103. Likewise, individuals with ischemic heart disease had a variable response to single intramyocardial vector administration, ranging from minimal neutralizing antibody levels to titers of 104. Evaluation of the data from all trials showed no correlation between the peak serum neutralizing anti-Ad response and the dose of Ad vector administered (P > 0.1, all comparisons). In contrast, there was a striking correlation between the peak anti-Ad5 neutralizing antibody levels evoked by vector administration and the level of preexisting anti-Ad5 antibodies (P = 0.0001). Thus, unlike the case for experimental animals, administration of Ad vectors to humans does not invariably evoke a systemic anti-Ad neutralizing antibody response. In humans, the extent of the response is dictated by preexisting antibody titers and modified by route of administration but is not dose dependent. Since the extent of anti-Ad neutralizing antibodies will likely modify the efficacy of administration of Ad vectors, these observations are of fundamental importance in designing human gene therapy trials and in interpreting the efficacy of Ad vector-mediated gene transfer.

Original languageEnglish
Pages (from-to)6729-6742
Number of pages14
JournalJournal of Virology
Volume73
Issue number8
Publication statusPublished - 1 Jan 1999
Externally publishedYes

Fingerprint

Humoral Immunity
Adenoviridae
Neutralizing Antibodies
Genes
Cystic Fibrosis
Colonic Neoplasms
Antibody Formation
Myocardial Ischemia
Complementary DNA
Cytosine Deaminase
Serum
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Harvey, B. G., Hackett, N. R., El-Sawy, T., Rosengart, T. K., Hirschowitz, E. A., Lieberman, M. D., ... Crystal, R. (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. Journal of Virology, 73(8), 6729-6742.

Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. / Harvey, Ben Gary; Hackett, Neil R.; El-Sawy, Tarek; Rosengart, Todd K.; Hirschowitz, Edward A.; Lieberman, Michael D.; Lesser, Martin L.; Crystal, Ronald.

In: Journal of Virology, Vol. 73, No. 8, 01.01.1999, p. 6729-6742.

Research output: Contribution to journalArticle

Harvey, BG, Hackett, NR, El-Sawy, T, Rosengart, TK, Hirschowitz, EA, Lieberman, MD, Lesser, ML & Crystal, R 1999, 'Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs', Journal of Virology, vol. 73, no. 8, pp. 6729-6742.
Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. Journal of Virology. 1999 Jan 1;73(8):6729-6742.
Harvey, Ben Gary ; Hackett, Neil R. ; El-Sawy, Tarek ; Rosengart, Todd K. ; Hirschowitz, Edward A. ; Lieberman, Michael D. ; Lesser, Martin L. ; Crystal, Ronald. / Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. In: Journal of Virology. 1999 ; Vol. 73, No. 8. pp. 6729-6742.
@article{51dbb0a5cbfb4640be08e0bdf01f2edc,
title = "Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs",
abstract = "Administration of adenovirus (Ad) vectors to immunologically naive experimental animals almost invariably results in the induction of systemic anti-Ad neutralizing antibodies. To determine if the human systemic humoral host responses to Ad vectors follow a similar pattern, we evaluated the systemic (serum) anti-Ad serotype 5 (Ad5) neutralizing antibodies in humans after administration of first generation (E1- E3-) Ad5-based gene transfer vectors to different hosts. Ad(GV)CFTR.10 (carrying the normal human cystic fibrosis [CF] transmembrane regulator cDNA) was sprayed (8 x 107 to 2 x 1010 particle units [PU]) repetitively (every 3 months or every 2 weeks) to the airway epithelium of 15 individuals with CF. Ad(GV)CD.10 (carrying the Escherichia coli cytosine deaminase gene) was administered (8 x 108 to 8 x 109 PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer and by the intradermal route (8 x 107 to 8 x 109 PU, single administration) to six healthy individuals. Ad(GV)VEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 108 to 4 x 109.5 PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease. Ad vector administration to the airways of individuals with CF evoked no or minimal serum neutralizing antibodies, even with repetitive administration. In contrast, intratumor administration of an Ad vector to individuals with metastatic colon cancer resulted in a robust antibody response, with anti-Ad neutralizing antibody titers of 102 to >104. Healthy individuals responded to single intradermal Ad vector variably, from induction of no neutralizing anti-Ad antibodies to titers of 5 x 103. Likewise, individuals with ischemic heart disease had a variable response to single intramyocardial vector administration, ranging from minimal neutralizing antibody levels to titers of 104. Evaluation of the data from all trials showed no correlation between the peak serum neutralizing anti-Ad response and the dose of Ad vector administered (P > 0.1, all comparisons). In contrast, there was a striking correlation between the peak anti-Ad5 neutralizing antibody levels evoked by vector administration and the level of preexisting anti-Ad5 antibodies (P = 0.0001). Thus, unlike the case for experimental animals, administration of Ad vectors to humans does not invariably evoke a systemic anti-Ad neutralizing antibody response. In humans, the extent of the response is dictated by preexisting antibody titers and modified by route of administration but is not dose dependent. Since the extent of anti-Ad neutralizing antibodies will likely modify the efficacy of administration of Ad vectors, these observations are of fundamental importance in designing human gene therapy trials and in interpreting the efficacy of Ad vector-mediated gene transfer.",
author = "Harvey, {Ben Gary} and Hackett, {Neil R.} and Tarek El-Sawy and Rosengart, {Todd K.} and Hirschowitz, {Edward A.} and Lieberman, {Michael D.} and Lesser, {Martin L.} and Ronald Crystal",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "73",
pages = "6729--6742",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs

AU - Harvey, Ben Gary

AU - Hackett, Neil R.

AU - El-Sawy, Tarek

AU - Rosengart, Todd K.

AU - Hirschowitz, Edward A.

AU - Lieberman, Michael D.

AU - Lesser, Martin L.

AU - Crystal, Ronald

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Administration of adenovirus (Ad) vectors to immunologically naive experimental animals almost invariably results in the induction of systemic anti-Ad neutralizing antibodies. To determine if the human systemic humoral host responses to Ad vectors follow a similar pattern, we evaluated the systemic (serum) anti-Ad serotype 5 (Ad5) neutralizing antibodies in humans after administration of first generation (E1- E3-) Ad5-based gene transfer vectors to different hosts. Ad(GV)CFTR.10 (carrying the normal human cystic fibrosis [CF] transmembrane regulator cDNA) was sprayed (8 x 107 to 2 x 1010 particle units [PU]) repetitively (every 3 months or every 2 weeks) to the airway epithelium of 15 individuals with CF. Ad(GV)CD.10 (carrying the Escherichia coli cytosine deaminase gene) was administered (8 x 108 to 8 x 109 PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer and by the intradermal route (8 x 107 to 8 x 109 PU, single administration) to six healthy individuals. Ad(GV)VEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 108 to 4 x 109.5 PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease. Ad vector administration to the airways of individuals with CF evoked no or minimal serum neutralizing antibodies, even with repetitive administration. In contrast, intratumor administration of an Ad vector to individuals with metastatic colon cancer resulted in a robust antibody response, with anti-Ad neutralizing antibody titers of 102 to >104. Healthy individuals responded to single intradermal Ad vector variably, from induction of no neutralizing anti-Ad antibodies to titers of 5 x 103. Likewise, individuals with ischemic heart disease had a variable response to single intramyocardial vector administration, ranging from minimal neutralizing antibody levels to titers of 104. Evaluation of the data from all trials showed no correlation between the peak serum neutralizing anti-Ad response and the dose of Ad vector administered (P > 0.1, all comparisons). In contrast, there was a striking correlation between the peak anti-Ad5 neutralizing antibody levels evoked by vector administration and the level of preexisting anti-Ad5 antibodies (P = 0.0001). Thus, unlike the case for experimental animals, administration of Ad vectors to humans does not invariably evoke a systemic anti-Ad neutralizing antibody response. In humans, the extent of the response is dictated by preexisting antibody titers and modified by route of administration but is not dose dependent. Since the extent of anti-Ad neutralizing antibodies will likely modify the efficacy of administration of Ad vectors, these observations are of fundamental importance in designing human gene therapy trials and in interpreting the efficacy of Ad vector-mediated gene transfer.

AB - Administration of adenovirus (Ad) vectors to immunologically naive experimental animals almost invariably results in the induction of systemic anti-Ad neutralizing antibodies. To determine if the human systemic humoral host responses to Ad vectors follow a similar pattern, we evaluated the systemic (serum) anti-Ad serotype 5 (Ad5) neutralizing antibodies in humans after administration of first generation (E1- E3-) Ad5-based gene transfer vectors to different hosts. Ad(GV)CFTR.10 (carrying the normal human cystic fibrosis [CF] transmembrane regulator cDNA) was sprayed (8 x 107 to 2 x 1010 particle units [PU]) repetitively (every 3 months or every 2 weeks) to the airway epithelium of 15 individuals with CF. Ad(GV)CD.10 (carrying the Escherichia coli cytosine deaminase gene) was administered (8 x 108 to 8 x 109 PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer and by the intradermal route (8 x 107 to 8 x 109 PU, single administration) to six healthy individuals. Ad(GV)VEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 108 to 4 x 109.5 PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease. Ad vector administration to the airways of individuals with CF evoked no or minimal serum neutralizing antibodies, even with repetitive administration. In contrast, intratumor administration of an Ad vector to individuals with metastatic colon cancer resulted in a robust antibody response, with anti-Ad neutralizing antibody titers of 102 to >104. Healthy individuals responded to single intradermal Ad vector variably, from induction of no neutralizing anti-Ad antibodies to titers of 5 x 103. Likewise, individuals with ischemic heart disease had a variable response to single intramyocardial vector administration, ranging from minimal neutralizing antibody levels to titers of 104. Evaluation of the data from all trials showed no correlation between the peak serum neutralizing anti-Ad response and the dose of Ad vector administered (P > 0.1, all comparisons). In contrast, there was a striking correlation between the peak anti-Ad5 neutralizing antibody levels evoked by vector administration and the level of preexisting anti-Ad5 antibodies (P = 0.0001). Thus, unlike the case for experimental animals, administration of Ad vectors to humans does not invariably evoke a systemic anti-Ad neutralizing antibody response. In humans, the extent of the response is dictated by preexisting antibody titers and modified by route of administration but is not dose dependent. Since the extent of anti-Ad neutralizing antibodies will likely modify the efficacy of administration of Ad vectors, these observations are of fundamental importance in designing human gene therapy trials and in interpreting the efficacy of Ad vector-mediated gene transfer.

UR - http://www.scopus.com/inward/record.url?scp=0032813559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032813559&partnerID=8YFLogxK

M3 - Article

C2 - 10400771

AN - SCOPUS:0032813559

VL - 73

SP - 6729

EP - 6742

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 8

ER -